Common immunological and prognostic features of lung and bladder cancer via smoking‐related genes: PRR11 gene as potential immunotherapeutic target
Journal of Cellular and Molecular Medicine · 2024
DOI: 10.1111/jcmm.18384 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Cellular and Molecular Medicine, 2024. Verfasst von YaXuan Wang und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Urology, The First Affiliated Hospital of Harbin Medical University, Harbin, China. Hauptthemen laut MEDLINE: Urinary Bladder Neoplasms, Lung Neoplasms, Smoking, Gene Expression Regulation, Neoplastic. Die Arbeit wurde bisher 12-mal zitiert (Crossref) und nennt 41 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Natural Science Foundation of China, Natural Science Foundation of Heilongjiang Province.
Abstract (Originalsprache)
Smoking is a well‐known risk factor for non‐small‐cell lung cancer (NSCLC) and bladder urothelial carcinoma (BLCA). Despite this, there has been no investigation into a prognostic marker based on smoking‐related genes that could universally predict prognosis in these cancers and correlate with immune checkpoint therapy. This study aimed to identify smoking‐related differential genes in NSCLC and BLCA, analyse their roles in patient prognosis and immune checkpoint therapy through subgroup analyses, and shed light on PRR11 as a crucial prognostic gene in both cancers. By examining PRR11 co‐expressed genes, a prognostic model was constructed and its impact on immunotherapy for NSCLC and BLCA was evaluated. Molecular docking and tissue microarray analyses were conducted to explore the correlation between PRR11 and its reciprocal gene SPDL1. Additionally, miRNAs associated with PRR11 were analysed. The study confirmed a strong link between smoking‐related genes, prognosis, and immune checkpoint therapy in NSCLC and BLCA. PRR11 was identified as a key smoking‐associated gene that influences the efficacy of immune checkpoint therapy by modulating the stemness of these cancers. A prognostic model based on PRR11 co‐expressed genes in BLCA was established and its prognostic value was validated in NSCLC. Furthermore, it was found that PRR11 regulates PDL1 via SPDL1, impacting immunotherapeutic efficacy in both cancers. The involvement of hsa‐miR‐200b‐3p in the regulation of SPDL1 expression by PRR11 was also highlighted. Overall, the study elucidates that PRR11 modulates patient immunotherapy by influencing PDL1 expression through its interaction with SPDL1, with potential upstream regulation by hsa‐miR‐200b‐3p.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Urology, The First Affiliated Hospital of Harbin Medical University, Harbin, China.
- Department of Central Laboratory, Affiliated Tumor Hospital of Nantong University & Nantong Tumor Hospital, Nantong, China.
ORCID-Profile: YaXuan Wang, MingHua Ren
Förderung
- National Natural Science Foundation of China
- Natural Science Foundation of Heilongjiang Province
Zitieren
APA
Wang, Y., Zhu, H., Zhang, L., He, J., Bo, J., Wang, J., Ding, B., & Ren, M. (2024). Common immunological and prognostic features of lung and bladder cancer via smoking‐related genes: PRR11 gene as potential immunotherapeutic target. Journal of Cellular and Molecular Medicine. https://doi.org/10.1111/jcmm.18384
Vancouver
Wang Y, Zhu H, Zhang L, He J, Bo J, Wang J, et al. Common immunological and prognostic features of lung and bladder cancer via smoking‐related genes: PRR11 gene as potential immunotherapeutic target. Journal of Cellular and Molecular Medicine. 2024. doi:10.1111/jcmm.18384
BibTeX
@article{Wang2024,
author = {Wang, YaXuan and Zhu, HaiXia and Zhang, Lu and He, JiaXing and Bo, Ji and Wang, JianShe and Ding, BeiChen and Ren, MingHua},
title = {Common immunological and prognostic features of lung and bladder cancer via smoking‐related genes: PRR11 gene as potential immunotherapeutic target},
journal = {Journal of Cellular and Molecular Medicine},
year = {2024},
doi = {10.1111/jcmm.18384}
}
EUVIMED